Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Frontline TKI in Intermediate-Risk Renal Cell Carcinoma

home / case-based-peer-perspectives / mcgregor-rcc

Frontline TKI in Intermediate-Risk Renal Cell Carcinoma

Case-Based Overview: Newly Diagnosed Renal Cell Carcinoma

EP. 1: Case-Based Overview: Newly Diagnosed Renal Cell Carcinoma

December 18th 2019

Watch

CABOSUN Trial: Cabozantinib vs Sunitinib for Renal Cell Carcinoma

EP. 2: CABOSUN Trial: Cabozantinib vs Sunitinib for Renal Cell Carcinoma

December 18th 2019

Watch

RCC: Treating Autoimmune Patients with Cabozantinib Versus Immunotherapy

EP. 3: RCC: Treating Autoimmune Patients with Cabozantinib Versus Immunotherapy

December 18th 2019

Watch

Factors Considered When Choosing RCC Treatment Options

EP. 4: Factors Considered When Choosing RCC Treatment Options

December 18th 2019

Watch

MOA and Management of Any Adverse Effects of Cabozantinib

EP. 5: MOA and Management of Any Adverse Effects of Cabozantinib

December 18th 2019

Watch

Other Trials and Combinations to Treat Renal Cell Carcinoma

EP. 6: Other Trials and Combinations to Treat Renal Cell Carcinoma

December 18th 2019

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.